Myeloid-derived suppressor cell

Myeloid Announces Appointment of Matthew Maurer, M.D. as Chief Medical Officer

Retrieved on: 
Wednesday, December 6, 2023
Renal cell carcinoma, Assistant, Bristol Myers Squibb, Therapy, Mechanical engineering, IND, Physician, Mount Sinai School, Biotechnology, Breast cancer, Patient, Medical Affairs Bureau, Myeloid-derived suppressor cell, Princeton University, Messenger, BSE, PARG, Myeloid tissue, Cancer, BMS, Immunotherapy, Mechanical, Pharmaceutical industry, Surgeon, Medicine, Vivo

CAMBRIDGE, Mass., Dec. 6, 2023 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage oncology company, has appointed Matthew Maurer, M.D.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 6, 2023 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage oncology company, has appointed Matthew Maurer, M.D.
  • as Chief Medical Officer.
  • "We are very pleased that Matt has joined Myeloid as our Chief Medical Officer.
  • Dr. Maurer received a BSE in Mechanical Engineering from Princeton University and earned his medical degree from the Mount Sinai School of Medicine.

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Retrieved on: 
Monday, November 6, 2023
MDSC, Consultant, Associate, Cancer immunotherapy, CD16, Therapy, Society for Immunotherapy of Cancer, Prostate cancer, MD, University, Myeloid-derived suppressor cell, GT, Doctor of Philosophy, Cell, Prostate, SITC, Immunotherapy, NK, Annual general meeting, PCA, Tumor microenvironment, Society, TME, PSMA, Hypoxia, Trike, Vaccine, Medicine

Natural killer (NK) cells are being increasingly explored in clinical trials due to their safety profile and ability to mediate tumor killing without prior priming.

Key Points: 
  • Natural killer (NK) cells are being increasingly explored in clinical trials due to their safety profile and ability to mediate tumor killing without prior priming.
  • However, lack of antigen-specific targeting, decreased numbers, and suppressive signals from the tumor microenvironment (TME) of Prostate Cancer (PCa), can negatively impact NK cell efficacy.
  • The TriKE molecules displayed improved tumor control, compared to IL-15 control or no treatment, in xenogeneic models of prostate cancer.
  • Society For Immunotherapy of Cancer (SITC) 2023 Annual Meeting – November 1-5, 2023

Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations

Retrieved on: 
Monday, November 6, 2023
Actinium, MDSC, Society for Immunotherapy of Cancer, NYSE, Annual Meetings of the International Monetary Fund and the World Bank Group, Myeloid-derived suppressor cell, Poster, SITC, Immunotherapy, Immunity, CD33, Society, Actinium-225, Escape Room, Vaccine

The poster highlighted Actimab-A's ability to target and deplete myeloid-derived suppressor cells (MDSCs), which uniformly express CD33.

Key Points: 
  • The poster highlighted Actimab-A's ability to target and deplete myeloid-derived suppressor cells (MDSCs), which uniformly express CD33.
  • MDSCs are a cell population of interest as they remodel the tumor environment and promote immune evasion.
  • Actinium believes Actimab-A has the potential to be used in combination with immunotherapy, including immune checkpoint inhibitors, to enhance antitumor immunity via targeted MDSC depletion.
  • Supportive data from the SITC presentation includes:
    Sandesh Seth, Actinium's Chairman and CEO, commented, "These data further increase our enthusiasm for Actimab-A's potential in solid tumor indications.

HighField Biopharmaceuticals Announces Positive Phase 1a Data of HF1K16, a new Immuno-Oncology Drug, For Patients with Recurrent and Refractory Glioma

Retrieved on: 
Monday, October 23, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ATRA, Survival, MDSC, Myeloid-derived suppressor cell, B cell, Partnering, Tumor microenvironment, Safety, Cancer, Patient, Myelocyte, Glioma, Pharmaceutical industry

“These encouraging results show HF1K16 is well tolerated and patients have experienced significant disease control,” said Yuhong Xu, CEO of HighField.

Key Points: 
  • “These encouraging results show HF1K16 is well tolerated and patients have experienced significant disease control,” said Yuhong Xu, CEO of HighField.
  • One of the other two patients, with grade IV glioblastoma, maintained stable disease for more than 4 months.
  • The third patient had stable disease for nearly 3 months and survival to date for more than 9 months.
  • The Phase 1b/2 trial, underway in China, and will assess safety and efficacy as well as evaluate changes in MDSC numbers and phenotypes.

The SparX Group Enters into a Collaboration with Arovella Therapeutics for the Development of CLDN18.2-CAR-iNKT Cell Therapy

Retrieved on: 
Tuesday, October 10, 2023
Partnership, Sparx, ASX, SPARX Group, Cell, Therapy, Myeloid-derived suppressor cell, Cytokine release syndrome, Mab, Safety, Hereditary diffuse gastric cancer, Tumor-associated macrophage, GC, MDSC, CD1D, Cancer, Tams, Fatality, Vaccine, Pharmaceutical industry

Dr. Gui-Dong Zhu, CEO of the SparX Group, elucidated on the significance of this collaboration: "Our partnership with Arovella represents a transformative phase in advancing mAb-based therapies.

Key Points: 
  • Dr. Gui-Dong Zhu, CEO of the SparX Group, elucidated on the significance of this collaboration: "Our partnership with Arovella represents a transformative phase in advancing mAb-based therapies.
  • Invariant Natural Killer T (iNKT) cells, distinguished by their recognition of lipid antigens via the CD1d molecule, have emerged as potent therapeutic vectors.
  • We profoundly acknowledge CLDN 18.2-iNKT cell therapy as a groundbreaking paradigm in oncological therapeutics."
  • The pathological architecture of tumor development often exposes the CLDN18.2, rendering it accessible to novel treatments such as CAR-iNKT cell therapies.

TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation

Retrieved on: 
Thursday, August 10, 2023
Health, Oncology, Clinical Trials, Well, LLP, Drug, Therapy, Liver disease, Myeloid-derived suppressor cell, Hepatocellular carcinoma, Neoplasm, Clinical trial, Pancreas, MDSC, Hope, Uveal melanoma, Cancer, MTAC, Toxicity, Foley & Lardner, Cholangiocarcinoma, Immunotherapy, JJ, ASCO, Cooley LLP, Patient, Blood, Liver, Growth, TLR, FDA, Hand, Environment, Medtech, MD Anderson Cancer Center, Tumor microenvironment, Pharmaceutical industry, Medical imaging

TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced the completion of its previously announced merger with MedTech Acquisition Corporation (Nasdaq: MTAC) (MedTech).

Key Points: 
  • TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced the completion of its previously announced merger with MedTech Acquisition Corporation (Nasdaq: MTAC) (MedTech).
  • “Completing our merger with MedTech marks an important milestone in our efforts to bring to market innovative approaches to treating liver and pancreatic tumors,” said Mary Szela, President and CEO of TriSalus.
  • Finally, I want to especially thank our MTAC and TriSalus shareholders for trusting us to create value for them.
  • Robust Device Pipeline: TriSalus' technology pipeline includes a range of devices that use technology expected to substantially improve therapeutic delivery.

HighField Biopharmaceuticals Announces First Patient Dosed in Phase 1b/2 Trial of HF1K16 for Recurrent and Refractory Glioma

Retrieved on: 
Monday, July 17, 2023
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Liposome, Glioma, Myelocyte, Glioblastoma, Myeloid-derived suppressor cell, American Society of Clinical Oncology, Clinical trial, Cancer, MDSC, Patient, ATRA, Diagnosis, Safety, Tumor microenvironment, B cell, Society, SD, Incidence, Vaccine, Medical imaging, Pharmaceutical industry

HighField Biopharmaceuticals (HighField Bio), a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced today the first patient has been dosed in a Phase 1b/2 trial of HF1K16 for recurrent and refractory glioma.

Key Points: 
  • HighField Biopharmaceuticals (HighField Bio), a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced today the first patient has been dosed in a Phase 1b/2 trial of HF1K16 for recurrent and refractory glioma.
  • “This clinical trial follows our analysis of interim data from a Phase 1a study in which three out of five glioma patients responded to the single agent treatment.
  • One achieved complete response (CR) and two more had stable disease (SD) diagnosis,” said Yuhong Xu, CEO of HighField Bio.
  • The patients with recurrent and refractory gliomas enrolled in HighField’s Phase 1b/2 trial have failed all other treatments.

HighField Biopharmaceuticals’ HF1K16, a New Immuno-Oncology Drug, Shows Promise in Patients with Refractory Glioblastoma

Retrieved on: 
Wednesday, May 31, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Glioma, Myelocyte, Progression-free survival, McCormick Place, Myeloid-derived suppressor cell, American Society of Clinical Oncology, RECIST, Cancer, Vitamin A, ASCO, MDSC, Patient, Annual general meeting, ATRA, Tumor microenvironment, B cell, Society, Safety, Medical imaging, Pharmaceutical industry

HighField Biopharmaceuticals (HighField Bio), a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced today the publication of an abstract including preliminary data from a Phase 1a clinical trial of HF1K16 in refractory metastatic cancer patients.

Key Points: 
  • HighField Biopharmaceuticals (HighField Bio), a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced today the publication of an abstract including preliminary data from a Phase 1a clinical trial of HF1K16 in refractory metastatic cancer patients.
  • The ASCO meeting is June 2 – 6, 2023, at the McCormick Place, Chicago, IL.
  • The preliminary data reported at ASCO is from an ongoing Phase 1a trial in China with patients suffering from a variety of refractory metastatic cancers.
  • Based on the positive findings related to glioma, HighField Bio expects to begin a Phase 1b/2 trial in China for patients with refractory glioma in the next few weeks.

Actinium Presents Data Demonstrating Actimab-A's Potential Use Against Solid Tumors by Selectively Depleting Immunosuppressive MDSCs, a Key Component of the Tumor Microenvironment, at the AACR Annual Meeting

Retrieved on: 
Wednesday, April 19, 2023
Actinium, AACR, Lintuzumab, Therapy, Myeloid-derived suppressor cell, Bone marrow, MDSC, American Association for Cancer Research, Immunity, NK, Research, Large intestine, Colorectal cancer, CD33, Annual general meeting, Tumor microenvironment, NYSE, Vaccine

NEW YORK, April 19, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, announced today the first ever data demonstrating the utility of Actimab-A to depleted myeloid derived suppressor cells (MDSCs), which are ubiquitously present within the solid tumor microenvironment as well as blood cancers. The new data were showcased in a poster presentation at the American Association for Cancer Research (AACR) 2023 Annual Meeting, which is being held April 14 - 19, 2023 in Orlando, Florida.

Key Points: 
  • The new data were showcased in a poster presentation at the American Association for Cancer Research (AACR) 2023 Annual Meeting, which is being held April 14 - 19, 2023 in Orlando, Florida.
  • At Actinium, we believe Actimab-A can play an important role in the tumor microenvironment by depleting MDSCs, which express CD33, in a targeted manner.
  • These data are an important step forward and we are excited to continue development of Actimab-A for MDSC depletion and beyond."
  • The poster will be available on the presentations page of Actinium's investor relations page of its website: https://ir.actiniumpharma.com/presentations-webinars .

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Retrieved on: 
Wednesday, April 19, 2023
STAT3, AACR, Phosphorylation, Myeloid-derived suppressor cell, IRS1, Neoplasm, American Association for Cancer Research, Hope, NK, ICB, Doctor of Philosophy, MD Anderson Cancer Center, Drug resistance, Protein, CD8, Patient, Melanoma, University, Annual general meeting, TME, Escape Room, Mouse, Tumor microenvironment, Pharmaceutical industry, Medical imaging

REHOVOT, Israel, April 19, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment (TME) to overcome tumor immune evasion and drug resistance, today shared new results presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando. The results demonstrate the potential of NT219, the Company’s novel small molecule dual inhibitor of IRS1/2 and STAT3 escape mechanisms, to work synergistically with either anti-PD1 or anti-CTLA4 drugs to reprogram the immune profile in the TME and convert resistant tumors to responders to Immune Checkpoint Blockage (ICB) therapies. The study was led by researchers at The University of Texas MD Anderson Cancer Center. Main results are as follows:

Key Points: 
  • The study was led by researchers at The University of Texas MD Anderson Cancer Center.
  • The induction of PDL1 by NT219 was much higher in the ICB-resistant melanoma strain as compared to ICB-sensitive cells, suggesting the potential to re-sensitize refractory tumors to anti-PD1 therapy.
  • Similarly, NT219 in combination with anti-PD1 showed synergistic effects inducing significant tumor growth inhibition of ICB-resistant tumors, while each therapy alone had no effect.
  • The full poster can be viewed on the Purple Biotech Website at https://purple-biotech.com/pipeline/#1Publications.